Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten
No clinically relevant changes in aficamten PK were observed in participants with moderate hepatic impairment. Population PK analysis indicated mild or moderate renal impairment and had no statistically or clinically significant impact on aficamten PK in patients with oHCM. Aficamten dose adjustment may not be necessary in patients with mild or moderate hepatic or renal impairment.
Authors
- Punag Divanji (ORCID: https://orcid.org/0000-0003-2868-4144)
- Polina German (ORCID: https://orcid.org/0000-0002-4516-6691)
- Stephen B. Heitner (ORCID: https://orcid.org/0000-0003-2189-1474)
- Stuart Kupfer (ORCID: https://orcid.org/0000-0002-5469-1287)
- Jianlin Li (ORCID: https://orcid.org/0000-0002-5267-3931)
- Donghong Xu
- Adrienne Griffith
- Justin D. Lutz
- Youcef Benattia
Institutions
- Cytokinetics (United States) (US)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1007/s40262-025-01481-9
- Citations
- 4
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.55
Funders
- Cytokinetics